MedTrace Logo

18F-FAPI PET in the Diagnosis of Liver Fibrosis

NCT05262647 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-03-02

No results posted yet for this study

Summary

It is an open label observation clinical trial, all participants are chronic liver disease. The investigators deem to make a novel evaluate criteria to hepatic fibrosis. The point of the clinical trial is to evaluate the novel biomaker 18F-FAPI-04 by PET-CT scan in the evaluation of the hepatic fibrosis.

Conditions

  • Liver Fibrosis
  • FAP
  • Positron Emission Tomography

Interventions

DIAGNOSTIC_TEST

18F-FAPI

Patients with chronic liver disease underwent 18F-FAPI-04 PET/CT and percutaneous liver biopsy.

Sponsors & Collaborators

  • The Affiliated Hospital of Qingdao University

    lead OTHER

Principal Investigators

  • Guangjie Yang, PhD · The affiliated hostpital of Qingdao University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-12
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05262647 on ClinicalTrials.gov